EichorEICHOR
Condition: Urinary Bladder Cancer Muscle Invasive Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Urinary Bladder Cancer Muscle Invasive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
NA · 2 location(s) · Johns Hopkins University · NCT07225205Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial
Phase N/A · 1 location(s) · OHSU Knight Cancer Institute · NCT07726602A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · Lumara Bio Oncologics GmbH · NCT05706129Impacts and Testing of the "Multi-domains Active-living Program" in Operable Non-Muscle Invasive Bladder Cancer Patients
NA · 1 location(s) · National Taiwan University Hospital · NCT05739968A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Phase 1 · 68 location(s) · Pfizer · NCT07206225Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
Phase N/A · 1 location(s) · Johns Hopkins University · NCT05672615A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Phase 1/Phase 2 · 20 location(s) · SURGE Therapeutics · NCT05710848Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
NA · 2 location(s) · Thomas Jefferson University · NCT07234968Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Pati
Phase 2 · 2 location(s) · University of Kansas Medical Center · NCT06493370Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging
Phase N/A · 1 location(s) · Oslo University Hospital · NCT07602010OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer
Phase 1/Phase 2 · 1 location(s) · Binhui Biopharmaceutical Co., Ltd. · NCT05232136FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer
NA · 1 location(s) · First Affiliated Hospital of Fujian Medical University · NCT06421142Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Phase 2 · 65 location(s) · CG Oncology, Inc. · NCT06567743Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer
Phase 2 · 3 location(s) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC · NCT03379909A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Phase 2 · 89 location(s) · Merck Sharp & Dohme LLC · NCT06833073Early vs Delayed Intravesical Blad-Care During BCG Therapy
NA · 1 location(s) · BLAD-HYA Group · NCT07495072Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
Phase 2 · 10 location(s) · White River Junction Veterans Affairs Medical Center · NCT05796375Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patie
Phase 2 · 3 location(s) · Yuanquan Yang · NCT06263153A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Phase 3 · 193 location(s) · Janssen Research & Development, LLC · NCT06319820Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasiv
Phase 2 · 1 location(s) · University Hospital, Ghent · NCT04724928Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
Phase 2 · 1 location(s) · Michael A. O'Donnell · NCT07322263Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
Phase N/A · 3 location(s) · Early is Good Inc. · NCT05982561Pan-tumor MRD Study
Phase N/A · 2 location(s) · Paradigm Health · NCT06605404Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder
Phase 2 · 71 location(s) · Protara Therapeutics · NCT05951179Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
Phase N/A · 6 location(s) · University of Washington · NCT07225127Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladde
Phase 2 · 1 location(s) · Shanxi Province Cancer Hospital · NCT07646145The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer
Phase 4 · 1 location(s) · Cairo University · NCT06215976To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients Wi
Phase 1/Phase 2 · 6 location(s) · RemeGen Co., Ltd. · NCT06378242Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
Phase 2 · 1 location(s) · Leslie Ballas · NCT06417190Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer
Phase 2 · 1 location(s) · Paul Toren · NCT07420517
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.